不寧腿綜合征為臨床常見中樞神經(jīng)系統(tǒng)感覺運動障礙性疾病,發(fā)病機制尚不明確,可能與遺傳因素或多巴胺能系統(tǒng)功能失調有關。加巴噴丁恩那卡比最初由美國XenoPort公司研發(fā),之后由英國葛蘭素史克公司通過并購獲得,臨床試驗驗證了其治療不寧腿綜合征的有效性。綜述了加巴噴丁恩那卡比的研發(fā)背景、合成方法、藥理學、藥動學、臨床評價、安全性和耐受性等研究進展,以期為臨床上更好地應用提供依據(jù)。

Restless legs syndrome (RLS) is a common clinical sensorimotor nervous system disorders. Its pathogenesis is uncertain and may be related to genetic factors or dopaminergic system dysfunction. Gabapentin enacarbil originally developed by the US company XenoPort, later was obtained by British GlaxoSmithKline through acquisitions, and clinical trials show the effectiveness of the treatment of RLS. This paper reviewed the research background, synthesis methods, pharmacology, pharmacokinetics, clinical evaluation, safety and tolerability of gabapentin enacarbil and provide the basis for better application in clinic.